US › Healthcare

Rein Therapeutics Inc (RNTX)

US · Healthcare · Biotechnology

$0.59-6.05%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-6.4M

EPS

$-0.10

EPS estimate

$-0.27

EPS came in at -0.10 against a street estimate of -0.27 — a beat of 63.0%.

Key statistics

Market cap

$65.1M

Forward P/E

0.0

P/B

6.52

Book value

$0.12

EPS (TTM)

$-1.68

52-week high

$2.18

52-week low

$0.54

50-day MA

$0.79

200-day MA

$1.08

Beta

1.35

Analyst view

Analysts rate Rein Therapeutics Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $6.00.

Shareholding

Insiders

5.02%

Institutions

52.37%

Largest institutional holders

Fund	Stake
Voss Capital LLC	6.10%
Cable Car Capital LLC	6.02%
ADAR1 Capital Management LLC	5.22%
Vanguard Capital Management, LLC	3.92%
BIOS CAPITAL MANAGEMENT, LP	3.46%
Ikarian Capital, LLC	3.42%
Great Point Partners LLC	2.98%
Citadel Advisors Llc	2.83%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Rein Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.